Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;44(2):385-403.
doi: 10.1007/s13402-020-00575-9. Epub 2021 Jan 19.

Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation

Henrique J Cardoso  1   2 , Marília I Figueira  1 , Cátia V Vaz  1 , Tiago M A Carvalho  1 , Luís A Brás  1 , Patrícia A Madureira  2   3 , Paulo J Oliveira  4 , Vilma A Sardão  4 , Sílvia Socorro  5
Affiliations

Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation

Henrique J Cardoso et al. Cell Oncol (Dordr). 2021 Apr.

Abstract

Purpose: Resistance to androgen-deprivation therapies and progression to so-called castrate-resistant prostate cancer (CRPC) remain challenges in prostate cancer (PCa) management and treatment. Among other alterations, CRPC has been associated with metabolic reprogramming driven by androgens. Here, we investigated the role of androgens in regulating glutaminolysis in PCa cells and determined the relevance of this metabolic route in controlling the survival and growth of androgen-sensitive (LNCaP) and CRPC (DU145 and PC3) cells.

Methods: PCa cells (LNCaP, DU145 and PC3) and 3-month old rats were treated with 5α-dihydrotestosterone (DHT). Alternatively, LNCaP cells were exposed to the glutaminase inhibitor BPTES, alone or in combination with the anti-androgen bicalutamide. Biochemical, Western blot and extracellular flux assays were used to evaluate the viability, proliferation, migration and metabolism of PCa cells in response to DHT treatment or glutaminase inhibition.

Results: We found that DHT up-regulated the expression of the glutamine transporter ASCT2 and glutaminase, both in vitro in LNCaP cells and in vivo in rat prostate cells. BPTES diminished the viability and migration of PCa cells, while increasing caspase-3 activity. CRPC cells were found to be more dependent on glutamine and more sensitive to glutaminase inhibition. BPTES and bicalutamide co-treatment had an additive effect on suppressing LNCaP cell viability. Finally, we found that inhibition of glutaminolysis differentially affected glycolysis and lipid metabolism in both androgen-sensitive and CRPC cells.

Conclusion: Our data reveal glutaminolysis as a central metabolic route controlling PCa cell fate and highlight the relevance of targeting glutaminase for CRPC treatment.

Keywords: 5α-dihydrotestosterone; ASCT2; BPTES; Bicalutamide; Castrate resistance; Glutamine; Glutaminolysis; Prostate cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. B.J. Altman, Z.E. Stine, C.V. Dang, From Krebs to clinic: Glutamine metabolism to cancer therapy. Nat. Rev. Cancer 16, 619–634 (2016) - PubMed - PMC
    1. D. Anastasiou, L.C. Cantley, Breathless cancer cells get fat on glutamine. Cell. Res. 22, 443–446 (2012) - PubMed - PMC
    1. S. Andersen, O. Solstad, L. Moi, T. Donnem, M. Eilertsen, Y. Nordby, N. Ness, E. Richardsen, L.T. Busund, R.M. Bremnes, Organized metabolic crime in prostate cancer: The coexpression of MCT1 in tumor and MCT4 in stroma is an independent prognosticator for biochemical failure. Urol. Oncol. 33, 338.e339–338.e317 (2015)
    1. D.A. Bader, S.M. Hartig, V. Putluri, C. Foley, M.P. Hamilton, E.A. Smith, P.K. Saha, A. Panigrahi, C. Walker, L. Zong, H. Martini-Stoica, R. Chen, K. Rajapakshe, C. Coarfa, A. Sreekumar, N. Mitsiades, J.A. Bankson, M.M. Ittmann, B.W. O’Malley, N. Putluri, S.E. McGuire, Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nat. Metab. 1, 70–85 (2019) - PubMed
    1. S. Bai, S. Cao, L. Jin, M. Kobelski, B. Schouest, X. Wang, N. Ungerleider, M. Baddoo, W. Zhang, E. Corey, R.L. Vessella, X. Dong, K. Zhang, X. Yu, E.K. Flemington, Y. Dong, A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer. Oncogene 38, 4977–4989 (2019) - PubMed - PMC

MeSH terms

LinkOut - more resources